TRIB2 contributes to cisplatin resistance in small cell lung cancer

Small cell lung cancer (SCLC) is the most aggressive lung-cancer subtype and so far, no favorable therapeutic strategy has been established for chemo-resistant SCLC. Cisplatin is one of the most important components among all standard poly-chemotherapeutic regimens for SCLC; therefore, this study fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yuanxin, Yu, Dong, Perez-Soler, Roman, Klostergaard, Jim, Zou, Yiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752545/
https://www.ncbi.nlm.nih.gov/pubmed/29312632
http://dx.doi.org/10.18632/oncotarget.22741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752545/
https://www.ncbi.nlm.nih.gov/pubmed/29312632
http://dx.doi.org/10.18632/oncotarget.22741

Ejemplares similares